Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response

Annals of Surgical Oncology

Volumn 19, Issue 1, 2012, Pages 253-258

  Fisher, Carla S ^a   Ma, Cynthia X ^a   Gillanders, William E ^a   Aft, Rebecca L ^a   Eberlein, Timothy J ^a   Gao, Feng ^a   Margenthaler, Julie A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84856670885     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1877-y     Document Type: Article

References (20)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer Statistics, 2009 CA Cancer J Clin. 59 225 249 19474385 10.3322/caac.20006
2. CK Anders LA Carey 2009 Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer Clin Breast Cancer. 9 suppl 2 S73 S81 19596646 10.3816/CBC.2009.s.008 1:CAS:528:DC%2BD1MXptlWgt7w%3D
3. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology. 52 108 118 18171422 10.1111/j.1365-2559.2007.02889.x 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D
4. E Rakha M El-Sayed A Green, et al. 2007 Prognostic markers in triple-negative breast cancer Cancer. 109 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D
5. JM Dolle JR Daling E White, et al. 2009 Risk factors for triple-negative breast cancer in women under the age of 45 years Cancer Epidemiol Biomarkers Prev. 18 1157 1166 19336554 10.1158/1055-9965.EPI-08-1005
6. LA Carey EC Dees L Sawyer L Gatti 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res. 13 2329 2334 17438091 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D
7. M Colleoni BF Cole G Viale, et al. 2010 Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer J Clin Oncol. 28 2966 2973 20458051 10.1200/JCO.2009.25.9549 1:CAS:528: DC%2BC3cXptlajtbY%3D
8. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res. 11 5678 5685 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D
9. AE Ring IE Smith S Ashley, et al. 2004 Estrogen receptor status, pathological complete response and prognosis in patietns receiving neoadjuvant chemotherapy for early stage breast cancer Br J Cancer. 91 2012 2017 15558072 10.1038/sj.bjc.6602235 1:CAS:528:DC%2BD2cXhtVOjsLbL
10. HD Bear S Anderson A Brown, et al. 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol. 21 4165 4174 14559892 10.1200/JCO.2003.12.005 1:CAS:528:DC%2BD2cXpsVajtrg%3D
11. M Colleoni I Minchella G Mazzarol, et al. 2000 Response to primary chemotherapy in breast cancer patients with tumors not expressiving estrogen and progesterone receptors Ann Oncol. 11 1057 1059 11038046 10.1023/A:1008334404825 1:STN:280:DC%2BD3cvoslOrug%3D%3D
12. M Colleoni G Viale D Zahrieh, et al. 2004 Chemotherapy is more effective in patients with breast cancer not expressiving steroid hormone receptors: A study of preoperative treatment Clin Cancer Res. 10 6622 6628 15475452 10.1158/1078-0432.CCR-04-0380 1:CAS:528:DC%2BD2cXot1Oiu7o%3D
13. C Liedtake C Mazouni KR Hess, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol. 26 1275 1281 10.1200/JCO.2007.14.4147
14. CR Kennedy F Gao JA Margenthaler 2010 Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer J Surg Res. 163 52 57 20599225 10.1016/j.jss.2010.04.015 1:CAS:528:DC%2BC3cXhtVanurvJ
15. N Wolmark J Wang E Mamounas J Bryant 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel project B-18 J Natl Cancer Inst Monogr. 30 96 102 11773300
16. P Rastogi SJ Anderson HD Bear, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27 J Clin Oncol. 26 778 785 18258986 10.1200/JCO.2007.15.0235
17. DP Silver AL Richardson AC Eklund, et al. 2010 Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol. 28 1145 1153 20100965 10.1200/JCO.2009.22.4725 1:CAS:528:DC%2BC3cXktF2ltLk%3D
18. Li X, Liu M, Zhang Y, et al. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2010. doi: 10.1007/s12032-010-9742-6.
19. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med. 361 123 134 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D
20. A Tutt M Robson JE Garber, et al. 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet. 376 235 244 20609467 10.1016/S0140-6736(10)60892-6 1:CAS:528:DC%2BC3cXpt1KktLc%3D